rdf-syntax-grammar
mods:
  schema location: http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
  title info:
    title: mTOR Inhibition for Cancer Therapy: Past, Present and Future
  name:
    name part: Mita, Monica.
    role:
      role term: editor.
  name:
    name part: Mita, Alain.
    role:
      role term: editor.
  name:
    name part: Rowinsky, Eric K.
    role:
      role term: editor.
  name:
    name part: SpringerLink (Online service)
  type of resource: text
  origin info:
    place:
      place term: fr
    date issued: 2016
    edition: 1st ed. 2016.
    issuance: monographic
  language:
    language term: eng
  physical description:
    form: electronic
    form: electronic resource
    reformatting quality: access
    form: remote
    extent: VI, 300 p. 16 illus., 13 illus. in color. online resource.
  abstract: This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compounds currently under evaluation.
  table of contents: Forward -- Past -- mTOR inhibitors: a little bit of history -- Present -- The mTOR pathway -- The evolving role of mTOR inhibitors in renal cell carcinoma -- The role of mTOR inhibitors in breast cancer -- The role of mTOR inhibitors in neuroendocrine tumors -- New indications of mTOR inhibitors in rare tumors -- The role of mTOR inhibitors in the treatment of hematological malignancies -- The clinical pharmacology and toxicity profile of rapalogs -- Resistance to mTOR inhibitors -- Rational combinations of mTOR inhibitors as anticancer strategies -- Future -- Predictive biomarkers of response to mTOR inhibitors -- The potential future indication of rapamycin analogs for the treatment of other solid tumors -- mTOR inhibition beyond rapalogs -- mTOR, aging and cancer: the missing link? -- New study design for mTOR inhibitors and other biological agents -- Future directions for the development of mTOR inhibitors.
  note: edited by Monica Mita, Alain Mita, Eric K. Rowinsky.
  subject:
    topic: Medicine
  subject:
    topic: Molecular biology
  subject:
    topic: Hematology
  subject:
    topic: Oncology
  subject:
    topic: Medicine & Public Health
  subject:
    topic: Oncology
  subject:
    topic: Hematology
  subject:
    topic: Molecular Medicine
  classification: RC254-282
  classification: 616.994
  related item:
    title info:
      title: Springer eBooks
  identifier: 9782817804927
  identifier: http://dx.doi.org/10.1007/978-2-8178-0492-7
  record info:
    record creation date: 151118
    record change date: 20151207141023.0
    record identifier: 978-2-8178-0492-7